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Abstract 
Review on SFRP2, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: FRP-2, SARP1, SDF-5 
HGNC (Hugo): SFRP2 
Location: 4q31.3 
Note: Orientation: minus strand. 
DNA/RNA 
Description 
Size: 8487 bases. The SFRP2 gene is located on the 
long arm of Chromosome 4, and consists of 3 
coding exons, with exon 2 being significantly 
smaller than the other two. No known splice 
variants. 
Transcription 
mRNA size 2005 bp, ORF size 888 bp. 
Protein 
Description 
SFRP2 contains several domains which potentially 
govern protein-protein interactions. 
- Beginning at the N-terminus there is a 24 aa 
hydrophobic signal domain, which presumably 
governs the targeting of SFRP2 to the secretory 
pathway. 
- The CRD/FZ (cysteine-rich/Frizzled) domain 
allows SFRP proteins to antagonise Wnt/Frizzled 
binding at the plasma membrane either by 
sequestration of the Wnt ligand or dominant-
negative binding to complimentary regions within 
the Frizzled protein. 
- The C345C/Netrin domain is an accessory binding 
domain for SFRP2-Wnt interaction. 
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Wnt (wingless-type)/β-catenin signaling is a major regulator of cell proliferation, migration and differentiation, 
controlling tissue homeostasis and tumor progression (Klaus et al., 2008). A) The binding of a canonical Wnt ligand to its 
cell-surface receptor complex, consisting of Frizzled (FZD) and one of two low-density-lipoprotein- receptor-related proteins 
(LRP-5 and LRP-6), initiates a signaling cascade that activates disheveled (DVL), which releases β-catenin from an inhibitory 
complex consisting of Axin, APC and glycogen synthase kinase 3b (GSK3B). On dephosphorylation and release, β-catenin 
translocates to the nucleus, where it interacts with members of the T-cell factor/lymphoid enhancer factor (TCF/LEF) families of 
transcription factors to stimulate expression of genes involved in cell survival, proliferation and osteoblastic differentiation (e.g., 
MMPs, CCND1, PTGS2, MYC, JUN and VEGFR) (Reya et al., 2005). B) Wnt signaling is regulated by several classes of 
negative regulators. The Secreted Frizzled-Related Protein (SFRP) class comprises SFRP1-SFRP5, Wnt inhibitory factor 1 
(WIF1) and Cerberus. SFRPs are a family of soluble glycoproteins that possess a cysteine- rich domain (CRD) structurally 
similar to the extracellular Wnt-binding domain of the FZD receptors. SFRPs can thus modulate Wnt signaling by sequestering 
Wnts through their CRD or by acting as dominant-negative inhibitors, forming inactive complexes with the FZD receptors. 
 
- The PDZ ligand domain is a short sequence which 
is recognised by PDZ proteins such as Dishevelled 
(Dvl), and other proteins which interact with the 
cytoplasmic portion of Frizzled (Schulte and Bryja, 
2007). Notably, a recent study (Zhang et al., 2009) 
has used synthetic PDZ ligands to interfere with 
Dvl/FZD cytoplasmic interaction, and thus 
antagonise canonical Wnt signalling. Additionally, 
another group subsequently showed that the NSAID 
Sulindac inhibits canonical Wnt signaling by 
blocking the PDZ domain of Dvl (Lee et al., 2009). 
These data suggest that the presence of a PDZ 
ligand in SFRP2 may indicate a previously-
unexplored role for SFRP2 as a cytoplasmic 
antagonist of Wnt signalling. 
- A phosphoproteomic study has revealed 
phosphorylation of SFRP2 at serine-289 in response 
to growth factor stimulation (Olsen et al., 2006). 
Bioinformatic analysis suggests that this site is a 
motif for recognition and phosphorylation by PKA. 
Additionally, bioinformatic analysis of the SFRP2 
sequence suggests a site for phosphorylation by 
GSK3β (itself an inhibitor of β-catenin) at either 
serine-34 or serine-38. Although the potential 
significance of phosphorylation at this site is 
unclear, it may overlap with the Nec 1/Nec 2 
cleavage site and prevent removal of the N-terminal 
signal domain. Typically, Nec 1/2 is responsible for 
the cleavage of pro-proteins into their active form, 
and perhaps phosphorylation in this region is a 
mechanism by which GSK3β may regulate SFRP2 
activity. 
Expression 
Widely expressed. 
Localisation 
Nucleus, cytoplasm and secreted. 
Function 
SFRP2 is a member of the secreted Frizzled-related 
protein (SFRP) family of soluble extracellular Wnt 
antagonists, which act in conjunction with the 
Dickkopf (DKK) class of Wnt antagonists. SFRP2 
is thought to act primarily by binding directly to 
and sequestering Wnt ligands, but may also act by 
direct binding to the Wnt-receptor complex. 
Binding occurs primarily via the cysteine-rich 
domain, which bears a high degree of homology to 
SFRP2 (secreted frizzled-related protein 2) O'Donovan DS, Perry AS 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(3) 182 
similar domains in the Frizzled (Fzd) receptor. 
SFRP activity may conversely promote Wnt 
pathway signalling in some contexts, as a 
consequence of SFRP proteins interacting with each 
other and titrating each others' activity, or by SFRP 
binding and stabilising Wnt-Fzd complexes. 
Homology 
SFRP2 has a high degree of homology to both other 
SFRP family members, as well as Fzd receptors via 
the cysteine-rich domain. 
Implicated in 
Colorectal cancer and prostate 
cancer 
Note 
Methylation of SFRP2 and its promoter regions, 
and consequent loss of SFRP2 expression, is a 
potential diagnostic and prognostic marker of 
disease progression in both colorectal and prostate 
cancers. 
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